NL
DE
7 October 2019
Raphaël Duivenvoorden, theme Renal disorders, together with Willem Mulder (Eindhoven University of Technology and Icahn School of Medicine at Mount Sinai in New York), Tina Binderup (University of Copenhagen) and Sherrill Fay (Icahn School of Medicine at Mount Sinai in New York) and their colleagues, developed a simvastatin-loaded high-density lipoprotein (S-HDL) – nanoparticle.
In a mouse model they showed that S-HDL nanoparticles inhibit inflammation in blood vessel walls, a process that drives atherosclerosis development. Subsequently they tested methods to scale up S-HDL nanoparticle production, a critical step needed for larger animal studies. Using advanced imaging techniques, they show that the scaled up nanoparticles exhibited anti-inflammatory effects in the blood vessels of atherosclerosis in rabbit and pig models, thereby reducing atherosclerosis.
This study highlights the challenges posed by scaling a nanotherapy for use in larger animal models and strategies to overcome these challenges.
Raphaël Duivenvoorden, theme Renal disorders, together with Willem Mulder (Eindhoven University of Technology and Icahn School of Medicine at Mount Sinai in New York), Tina Binderup (University of Copenhagen) and Sherrill Fay (Icahn School of Medicine at Mount Sinai in New York) and their colleagues, developed a simvastatin-loaded high-density lipoprotein (S-HDL) – nanoparticle.
In a mouse model they showed that S-HDL nanoparticles inhibit inflammation in blood vessel walls, a process that drives atherosclerosis development. Subsequently they tested methods to scale up S-HDL nanoparticle production, a critical step needed for larger animal studies. Using advanced imaging techniques, they show that the scaled up nanoparticles exhibited anti-inflammatory effects in the blood vessels of atherosclerosis in rabbit and pig models, thereby reducing atherosclerosis.
This study highlights the challenges posed by scaling a nanotherapy for use in larger animal models and strategies to overcome these challenges.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Academic collaboration agreement between UTwente and Radboudumc
23 November 2021 The group of Biomaterials Science and Technology (BST) of the Faculty of Science and Technology at the TechMed centre of University of Twente has signed a formal academic collaboration agreement with the departments of Nephrology and Physiology at Radboudumc. read more
Molecular scissors play a role in kidney and lung leakage in COVID-19 patients
18 June 2020 ‘Molecular scissors', play a role in leakage of fluid from blood vessels to lungs and kidneys in COVID-19 patients. The scissors cut the protective sugar layer in the blood vessels. The more serious the disease, the more active the scissors, wrote Johan van der Vlag and colleagues in MedRxiv. read more.aspx?width=2120&height=1414&ext=.jpg&type=BlockColumn1Zoom1)
New insight into the effect of hydroxychloroquine undermines its use in corona
11 June 2020 Researchers at Radboud university medical center have discovered an as yet unknown effect of hydroxychloroquine. Raphael Duivenvoorden was interviewed in the program Op1 at NPO1 to elaborate on the findings. It seems unlikely that chloroquine has beneficial effect in corona infections. read moreJohan van der Vlag appointed as professor of Immunology of Kidney Diseases and Transplantation
23 April 2020 Johan van der Vlag is an expert in unravelling the molecular and immunological mechanisms underlying kidney disease and transplantation. His research stems from clinical questions and focuses on the development of new diagnostic/prognostic and therapeutic strategies. read more
Dutch Kidney Foundation PhD grant for Johan van der Vlag and Tom Nijenhuis
14 February 2020 Johan van der Vlag and Tom Nijenhuis, theme Renal disorders, received this grant for their joint research project “Targeting a novel paracrine signaling pathway between glomerular endothelium and podocytes to treat glomerular injury”. read more
